Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 14/20 | 0.58 |
| ▸ | AR | P10275 | 3/20 | 0.57 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148159 | 1.00 | LMNA (0.59) | LMNAPARP1ARENPP1CYP3A4 | |
| SCHEMBL30792539 | 1.00 | LMNA (0.59) | LMNAPARP1ARENPP1CYP3A4 | |
| SCHEMBL31621084 | 0.89 | PRMT5 (0.49) | LMNAPARP1ENPP1 | |
| SCHEMBL28468170 | 0.89 | LMNA (0.60) | LMNAPARP1ARENPP1CYP3A4 | |
| SCHEMBL31621075 | 0.88 | PARP1 (0.47) | LMNAPARP1ENPP1 | |
| SCHEMBL13384006 | 0.88 | LMNA (0.59) | LMNAPARP1ARENPP1CYP3A4 | |
| SCHEMBL87069 | 0.87 | PARP1 (0.47) | LMNAPARP1ENPP1 | |
| SCHEMBL31621078 | 0.87 | PARP1 (0.47) | LMNAPARP1ENPP1 | |
| SCHEMBL12955373 | 0.84 | LMNA (0.68) | LMNAPARP1ARENPP1CYP3A4 | |
| SCHEMBL86923 | 0.84 | PARP1 (0.53) | LMNAPARP1ARENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448886-A | Preparation method of olapari | 福建福瑞明德药业有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-2824098-B1 | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARM LTD (GB) | 2016-06-22 | — | — | EP | claimed |
| EP-2824098-A1 | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2015-01-14 | — | — | EP | claimed |
| CN-102627611-A | Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARM LTD | 2012-08-08 | — | — | CN | claimed |
| EP-2374800-A2 | Methods for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2011-10-12 | — | — | EP | claimed |
| US-7692006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| CN-101528714-A | Polymorphs of 4- [ 3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one | KUDOS PHARM LTD (GB) | 2009-09-09 | — | — | CN | claimed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | claimed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | claimed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
| CN-117736150-A | Method for efficiently synthesizing key intermediate of Olaparib and application thereof | 北京海美源医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115448886-A | Preparation method of olapari | 福建福瑞明德药业有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115448886-A | Preparation method of olapari | 福建福瑞明德药业有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20180057464-A1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN, LTD. (TW) | 2018-03-01 | — | — | US | disclosed |
| US-20180057464-A1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN, LTD. (TW) | 2018-03-01 | — | — | US | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057464-A1 | PROCESSES FOR PREPARING OLAPARIB | PARP1, PARP2, PARP3 | LMNA 1106/4885PARP1 1/4885AR 648/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | LMNA 1387/4885PARP1 1/4885AR 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.